New drug cocktail shows promise in shrinking ovarian tumors before surgery
NCT ID NCT07407452
First seen Feb 15, 2026 · Last updated May 19, 2026 · Updated 19 times
Summary
This study tests a new combination of drugs (iparomlimab, tuvonralimab, chemotherapy, and olaparib) given before surgery to shrink advanced ovarian cancer. About 50 women will receive 3 cycles of treatment, then doctors will check if the tumor has shrunk enough for surgery. The goal is to see if this approach is safe and helps remove more cancer during surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.